Skip to content

Study · Systematic review · n = 25,957 · 2024

7 results

Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.

Zhang HD, Ding L, Liu K, Mi LJ, Zhang AK, Yu FY, Yan XX, Peng FH, Shen YJ, Tang M

Diabetes & metabolic syndrome27 Jun 2024Cited by 19 (Europe PMC)

PMID38955095 (opens in a new tab)DOI10.1016/j.dsx.2024.103067 (opens in a new tab)PepBankPUB-38955095
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, obesity or overweight, semaglutide decreased atrial fibrillation occurrence compared with control drugs.

    In plain wordsIn people with type 2 diabetes, obesity or overweight, semaglutide lowered the chance of atrial fibrillation compared with control drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAtrial fibrillation occurrence, overall
    Study

    n = 25,957

    Comparator
    Control drugs
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    0.7 ratio
    overall

    Source sentences

    Summary
    In the overall pooled analysis, semaglutide decreased AF occurrence compared to control drugs (RR 0.70, 95 % CI 0.52-0.95).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In trials with other antihyperglycemic medications as controls, semaglutide decreased atrial fibrillation occurrence.

    In plain wordsIn trials that compared semaglutide with other diabetes drugs, semaglutide lowered the chance of atrial fibrillation.

    Peptide
    Semaglutide
    Outcome
    DecreaseAtrial fibrillation occurrence, other antihyperglycemic controls
    Study

    n: not reported in source

    Comparator
    Other antihyperglycemic medications
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    0.43 ratio
    other antihyperglycemic controls

    Source sentences

    Summary
    This result was consistent in trials using other antihyperglycemic medications as controls (RR 0.43, 95 % CI 0.21-0.89), but not in placebo-controlled trials (RR 0.77, 95 % CI 0.56-1.07).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In placebo-controlled trials, semaglutide did not significantly change atrial fibrillation occurrence.

    In plain wordsIn trials that compared semaglutide with placebo, semaglutide did not clearly change the chance of atrial fibrillation.

    Peptide
    Semaglutide
    Outcome
    No significant changeAtrial fibrillation occurrence, placebo-controlled trials
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    0.77 ratio
    placebo-controlled trials

    Source sentences

    Summary
    This result was consistent in trials using other antihyperglycemic medications as controls (RR 0.43, 95 % CI 0.21-0.89), but not in placebo-controlled trials (RR 0.77, 95 % CI 0.56-1.07).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, semaglutide decreased atrial fibrillation occurrence compared with control drugs.

    In plain wordsIn people with type 2 diabetes, semaglutide lowered the chance of atrial fibrillation compared with control drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAtrial fibrillation occurrence, type 2 diabetes
    Study

    n: not reported in source

    Comparator
    Control drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    0.71 ratio
    type 2 diabetes

    Source sentences

    Summary
    The outcome was favorable for patients with T2DM (RR 0.71, 95 % CI 0.52-0.97), but not for patients with overweight or obesity (RR 0.56, 95 % CI 0.18-1.73).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In patients with overweight or obesity, semaglutide did not significantly change atrial fibrillation occurrence compared with control drugs.

    In plain wordsIn people with overweight or obesity, semaglutide did not clearly change the chance of atrial fibrillation compared with control drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeAtrial fibrillation occurrence, overweight or obesity
    Study

    n: not reported in source

    Comparator
    Control drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    0.56 ratio
    overweight or obesity

    Source sentences

    Summary
    The outcome was favorable for patients with T2DM (RR 0.71, 95 % CI 0.52-0.97), but not for patients with overweight or obesity (RR 0.56, 95 % CI 0.18-1.73).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, obesity or overweight, oral semaglutide decreased atrial fibrillation occurrence compared with control drugs.

    In plain wordsIn people with type 2 diabetes, obesity or overweight, semaglutide taken by mouth lowered the chance of atrial fibrillation compared with control drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAtrial fibrillation occurrence, oral semaglutide
    Study

    n: not reported in source

    Comparator
    Control drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Relative risk
    0.49 ratio
    oral semaglutide

    Source sentences

    Summary
    Results varied by type of semaglutide, with oral semaglutide showing an RR of 0.49 (95 % CI 0.25-0.97) and subcutaneous semaglutide showing an RR of 0.77 (95 % CI 0.55-1.07).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, obesity or overweight, subcutaneous semaglutide did not significantly change atrial fibrillation occurrence compared with control drugs.

    In plain wordsIn people with type 2 diabetes, obesity or overweight, injected semaglutide did not clearly change the chance of atrial fibrillation compared with control drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeAtrial fibrillation occurrence, subcutaneous semaglutide
    Study

    n: not reported in source

    Comparator
    Control drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Relative risk
    0.77 ratio
    subcutaneous semaglutide

    Source sentences

    Summary
    Results varied by type of semaglutide, with oral semaglutide showing an RR of 0.49 (95 % CI 0.25-0.97) and subcutaneous semaglutide showing an RR of 0.77 (95 % CI 0.55-1.07).
    2 context sentences
    Summary · context
    Randomized controlled trials of semaglutide in patients with T2DM, obesity, or overweight were included.
    Summary · context
    Twenty-one trials comprising 25957 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.